212 related articles for article (PubMed ID: 17980406)
21. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
Small EJ; Fontana J; Tannir N; DiPaola RS; Wilding G; Rubin M; Iacona RB; Kabbinavar FF
BJU Int; 2007 Oct; 100(4):765-9. PubMed ID: 17822457
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programme.
Ostoros G; Harisi R; Kovacs G; Horti J; Geczi L; Szondy K; Orosz M; Ferenczi E; Ruby E; Dome B
Anticancer Res; 2005; 25(6C):4759-62. PubMed ID: 16334173
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Kobayashi M; Matsui K; Katakami N; Takeda K; Moriyama A; Iwamoto Y; Takada M; Yoshioka H; Sueoka-Aragane N; Nakagawa K;
Jpn J Clin Oncol; 2011 Aug; 41(8):948-52. PubMed ID: 21715363
[TBL] [Abstract][Full Text] [Related]
25. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
Javle M; Pande A; Iyer R; Yang G; LeVea C; Wilding G; Black J; Nava H; Nwogu C
Am J Clin Oncol; 2008 Aug; 31(4):329-34. PubMed ID: 18845990
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.
Pearl ML; Johnston CM; McMeekin DS
Gynecol Obstet Invest; 2007; 64(4):193-8. PubMed ID: 17664880
[TBL] [Abstract][Full Text] [Related]
28. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
[TBL] [Abstract][Full Text] [Related]
29. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
30. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.
von Minckwitz G; Jonat W; Fasching P; du Bois A; Kleeberg U; Lück HJ; Kettner E; Hilfrich J; Eiermann W; Torode J; Schneeweiss A
Breast Cancer Res Treat; 2005 Jan; 89(2):165-72. PubMed ID: 15692759
[TBL] [Abstract][Full Text] [Related]
31. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of gefitinib in recurrent glioblastoma.
Rich JN; Reardon DA; Peery T; Dowell JM; Quinn JA; Penne KL; Wikstrand CJ; Van Duyn LB; Dancey JE; McLendon RE; Kao JC; Stenzel TT; Ahmed Rasheed BK; Tourt-Uhlig SE; Herndon JE; Vredenburgh JJ; Sampson JH; Friedman AH; Bigner DD; Friedman HS
J Clin Oncol; 2004 Jan; 22(1):133-42. PubMed ID: 14638850
[TBL] [Abstract][Full Text] [Related]
33. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients.
Hertlein L; Lenhard M; Kirschenhofer A; Kahlert S; Mayr D; Burges A; Friese K
Arch Gynecol Obstet; 2011 Jan; 283(1):109-13. PubMed ID: 20180130
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
35. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.
Moiseyenko VM; Procenko SA; Levchenko EV; Barchuk AS; Moiseyenko FV; Iyevleva AG; Mitiushkina NV; Togo AV; Semionov II; Ivantsov AO; Matsko DE; Imyanitov EN
Onkologie; 2010; 33(5):231-8. PubMed ID: 20502057
[TBL] [Abstract][Full Text] [Related]
36. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Cho BC; Im CK; Park MS; Kim SK; Chang J; Park JP; Choi HJ; Kim YJ; Shin SJ; Sohn JH; Kim H; Kim JH
J Clin Oncol; 2007 Jun; 25(18):2528-33. PubMed ID: 17577030
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
